Boston Scientific (BSX)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$44.80-1.09%
Close 2026-07-08 · 1-day change
Reading BSX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BSX free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading BSX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BSX free→QuarterlyIQ Insights · BSX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. Investment Agreement with MiRus LLC On May 18, 2026, Boston Scientific Corporation (the “ Company ”) issued a press release announcing that the Company has entered into an investment agreement (the “ Investment Agreement ”) with MiRus LLC (“ MiRus ”), a privately held company developing and commercializing proprietary novel biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the Siegel transcatheter aortic valve…
Other Events. Accelerated Share Repurchase Program On May 18, 2026, Boston Scientific Corporation (the “ Company ”) issued a press release announcing that the Company has entered into an accelerated share repurchase (“ ASR ”) agreement with JPMorgan Chase Bank, National Association for $2 billion (the “ Repurchase Price ”) of its common stock, as part of its previously announced $5 billion share repurchase authorization. Under the terms of the ASR, the Company will pay the repurchase price an…
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. With respect to the 2026 Credit Agreements, the information set forth above under
Entry into a Material Definitive Agreement. Revolving Credit Agreement On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. The Company may borrow from time to time up to $3,000,000,000 in revolving credit loans under the 2026 Revolving C…
Termination of a Material Definitive Agreement. In connection with the entry into the 2026 Revolving Credit Agreement, on February 26, 2026, the Company terminated a prior revolving credit agreement, dated as of May 10, 2021, as amended by that certain Amendment to the Credit Agreement dated as of December 21, 2022, the Second Amendment to the Credit Agreement, dated as of March 1, 2023, and the Third Amendment to the Credit Agreement, dated as of May 10, 2024, by and among the Company, as bo…
Other Events. On February 18, 2026, the Board approved an increase to the Company’s existing authorization to repurchase up to $1.0 billion of the Company’s common stock, par value $0.01 per share (“ Common Stock ”), by an additional $4.0 billion. As a result, the Company is authorized to repurchase up to a total of $5.0 billion of Common Stock under the Company’s stock repurchase program, all of which remains available as of the date hereof.
Director — Catherine R. Smith, Christophe P. Weber: The Board of Directors increased the number of directors and appointed two new external directors.
Director — Yoshiaki Fujimori: Mr. Yoshiaki Fujimori will not stand for re-election at the Company’s 2026 Annual Meeting.
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT On January 14, 2026, Boston Scientific Corporation, a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Pinehurst Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub ”), and Penumbra, Inc., a Delaware corporation (“ Penumbra ”), providing for the merger of Merger Sub with and into Penumbra (the “ Merger ”), with Penumbra surviving the Merg…
of this Current Report on Form 8-K, as well as Exhibit 99.1 and Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “ Securities Act ”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Cautionary Statement Regarding Forward-…
The filing describes a new annual bonus plan for employees, including executives.
Director — John E. Sununu: Mr. Sununu will not stand for re-election at the Company’s 2026 Annual Meeting.
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Executive Vice President and President, Peripheral Interventions — Jeffrey B. Mirviss: Mr. Jeffrey B. Mirviss is retiring from his role and will serve as a senior advisor until February 27, 2026.
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Other Events. On May 28, 2025, Boston Scientific Corporation (the “Company”) announced it is discontinuing worldwide sales of the ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems and no longer pursuing U.S. FDA approval for ACURATE or approval in other geographies. The Company made this decision based on recent discussions with regulators, which resulted in increased clinical and regulatory requirements to maintain regulatory approvals in global markets and to obtain approvals in new reg…
Chief Financial Officer — Daniel J. Brennan and Jonathan Monson: Daniel J. Brennan is retiring as CFO, and Jonathan Monson has been promoted to replace him.
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Creation of a Direct Financial Obligation of a Registrant. The information set forth under
Entry into a Material Definitive Agreement. On February 21, 2025, Boston Scientific Corporation (the “Company”), as guarantor, and American Medical Systems Europe B.V. (“AMS Europe”), its wholly owned finance subsidiary, as issuer, entered into an Underwriting Agreement (as supplemented by the Terms Agreement, also dated February 21, 2025, the “Underwriting Agreement”), among the Company, AMS Europe and the several underwriters named in the Underwriting Agreement (the “Underwriters”), in conn…
Other Events. On February 26, 2025, AMS Europe completed the offering of the Notes. The net proceeds from the offering of the Notes, after deducting the underwriting discount and estimated offering expenses payable by us, were approximately €1.487 billion. The Company intends to use the net proceeds from the offering of the Notes, together with cash on hand, to fund the repayment at maturity of AMS Europe’s 0.750% Senior Notes due March 8, 2025, and to pay accrued and unpaid interest with res…
Director — Charles J. Dockendorff: Mr. Dockendorff will not stand for re-election at the Company's 2025 Annual Meeting.
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.